Related Experiment Video

Updated: Sep 20, 2025

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.2K

Indian experience with immunotherapy in sarcoma and gastrointestinal stromal tumors: a retrospective study

Rohit Reddy1, Raja Mounika Velagapudi2, Sindhura Durga Chitikela1

  • 1Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.

Future Science OA
|June 6, 2022
PubMed
Abstract

Insights

Checkpoint inhibitors (CPI) showed limited efficacy in advanced sarcoma and gastrointestinal stromal tumors in India. Further clinical trials are needed to evaluate their role in these rare cancers.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Sarcomas and gastrointestinal stromal tumors (GIST) are rare cancers with limited treatment options.
  • Checkpoint inhibitors (CPI) have revolutionized cancer treatment but their efficacy in these specific tumor types is less understood.

Purpose of the Study:

  • To investigate the real-world effectiveness and safety of CPI in patients with advanced sarcoma and GIST in India.
  • To establish a baseline for future clinical trials evaluating CPI in these populations.

Main Methods:

  • Retrospective analysis of 15 patients with advanced sarcoma or GIST treated with CPI.
  • Data collection included treatment response, progression-free survival (PFS), overall survival (OS), and adverse events.

Main Results:

  • A limited overall response rate of 21.4% was observed.
  • Disease control rate was 42.8%.
  • Median PFS was 4 months and median OS was 14 months, with 73.3% of patients progressing.

Conclusions:

  • This study provides initial real-world data on CPI use in Indian sarcoma and GIST patients.
  • The observed efficacy was modest, suggesting CPI may have a limited role in these cancers.
  • Further prospective clinical trials are warranted to confirm these findings and explore potential predictive biomarkers.
Keywords:
GISTalveolar soft-part sarcomacheckpoint inhibitorsdisease control rateimmune-related toxicitiesimmunotherapysarcomaundifferentiated pleomorphic sarcoma

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.3K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
677
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K